ClinicalTrials.gg
CompletedNCT07219017Updated Jan 5, 2026

A Study to Assess the Mass Balance of Oral ABBV-1354 in Healthy Adult Male Participants

A Phase 1 interventional study of ABBV-1354 in Healthy Volunteer, sponsored by AbbVie. Completed at 1 site in United States. Open to male participants aged 18 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-01-05.

Sponsored by AbbVie · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
8
Allocation
Not applicable
Ages
18 Years to 60 Years
Sex
Male
01

Study summary

This study is to assess the mass balance of oral ABBV-1354 in healthy adult male participants.

02

Conditions studied

  • Healthy Volunteer

Keywords

  • Healthy Volunteer
  • ABBV-1354
03

In context

Lead sponsor

AbbVie is the lead sponsor of 977 studies on the registry; 136 are open to participants now.

Of its 359 completed or terminated interventional studies of FDA-regulated products, 215 (60%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male participants are eligible to participate if they agree to the following from Study Day 1 and for at least 93 days after the last dose of study treatment:
  • Refrain from donating sperm

PLUS, either:

- Practice true abstinence, defined as: Refraining from heterosexual intercourse when this is in line with the preferred and usual lifestyle of the subject. Periodic abstinence (e.g., calendar, ovulation, symptothermal, post-ovulation methods) and withdrawal are not acceptable.

OR

  • Use a male condom with spermicide (even with a successful vasectomy) with female partner who also uses a highly effective method with a failure rate of \< 1% per year (when used consistently and correctly).

AND

  • Advise of the benefit for a female partner to use a highly effective method of contraception (as a condom may break or leak) if having sexual intercourse with a woman of who is not currently pregnant.
  • is ≥ 18.0 to ≤ 32.0 kg/m2 after rounding to the tenths decimal at Screening. BMI is calculated as weight in kg divided by the square of height measured in meters.
  • A condition of general good health, based upon the results of a medical history, physical examination, vital signs, laboratory profile and a 12-lead .

Exclusion criteria

Exclusion Criteria:

  • History: of epilepsy, any cardiac, respiratory (except mild asthma as a child), endocrine, metabolic, renal, hepatic, gastrointestinal, hematologic or psychiatric disease or disorder, or any uncontrolled medical illness.
  • History of any clinically significant sensitivity or allergy to any medication or food.
  • History of or active medical condition(s) or surgical procedure(s) that might affect gastrointestinal motility, pH, or absorption [e.g., Crohn's disease, celiac disease, gastroparesis, short bowel syndrome, gastric surgery (except pyloromyotomy for pyloric stenosis during infancy), cholecystectomy, vagotomy, bowel resection, etc.].
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
8 participants (actual)

Study arms

  • Experimental
    ABBV-1354

    Participants will receive a single dose of oral ABBV-1354 and followed 30 days post dose.

    Drug: ABBV-1354

Interventions

  • DrugABBV-1354

    Oral solution

06

What researchers measure

Primary outcomes

  1. Number of Participants with Adverse Events (AEs)

    An adverse event (AE) is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment.

    Time frame: Up to approximately 32 days

  2. Number of Participants with Abnormal Change from Baseline in Vital Sign Measurements

    Number of participants with abnormal change from baseline in vital sign measurements like systolic and diastolic blood pressure will be assessed.

    Time frame: Up to approximately 15 days

  3. Change From Baseline in Electrocardiograms (ECGs)

    12-lead resting ECG will be recorded.

    Time frame: Up to approximately 15 days

  4. Number of Participants with Abnormal Change in Physical Examinations

    Number of participants with abnormal change in physical examinations in areas like cardiovascular, respiratory, gastrointestinal, and neurological systems will be assessed.

    Time frame: Up to approximately 15 days

  5. Number of Participants with Abnormal Change in Clinical Laboratory Test Results Like Hematology will be Assessed

    Number of participants with abnormal change in clinical laboratory test results like hematology will be assessed.

    Time frame: Up to approximately 15 days

  6. Maximum observed concentration (Cmax) of ABBV-1354

    Cmax of ABBV-1354 will be assessed.

    Time frame: Up to approximately 15 days

  7. Time to Cmax (peak time, Tmax) of ABBV-1354

    Max of ABBV-1354 will be assessed.

    Time frame: Up to approximately 15 days

  8. Terminal phase elimination half-life (t1/2) of ABBV-1354

    Terminal phase elimination half-life (t1/2) of ABBV-1354 will be assessed.

    Time frame: Up to approximately 15 days

  9. Area under the plasma concentration-time curve (AUC) from time 0 to the time of the last measurable concentration (AUCt) of ABBV-1354

    AUCt of ABBV-1354 will be assessed.

    Time frame: Up to approximately 15 days

  10. Area under the plasma concentration-time curve (AUC) from time 0 to infinite time (AUCinf) of ABBV-1354

    AUCinf of ABBV-1354 will be assessed.

    Time frame: Up to approximately 15 days

  11. Amount of ABBV-1354 excreted in the urine over the sampling period (Aeu)

    Amount of ABBV-1354 excreted in the urine over the sampling period (Aeu) will be assessed.

    Time frame: Up to approximately 15 days

  12. Percent of ABBV-1354 excreted in the urine

    Percent excreted = 100 × (Aeu/dose).

    Time frame: Up to approximately 15 days

  13. Amount of ABBV-1354 excreted in the feces over the sampling period (Aeu)

    Amount of ABBV-1354 excreted in the feces over the sampling period (Aeu) will be assessed.

    Time frame: Up to approximately 15 days

  14. Percent of ABBV-1354 radioactivity excreted in the feces

    Percent excreted = 100 × (Aeu/dose).

    Time frame: Up to approximately 15 days

07

Study locations

1 site
  • Fortrea Clinical Research Unit Inc /ID# 277011
    Madison, Wisconsin 53704, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2025 to primary completion in Dec 2025, 1 month.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 17, 2025
First posted
Oct 21, 2025
StartActual
Oct 15, 2025
Primary completionActual
Dec 9, 2025
CompletionActual
Dec 9, 2025
Last update
Jan 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 5, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07219017
Lead sponsor
AbbVie
Responsible party
Sponsor
First posted
Oct 21, 2025
Start date
Oct 15, 2025
Primary completion
Dec 9, 2025
Completion
Dec 9, 2025
Last update
Jan 5, 2026

Study contacts

ABBVIE INC.
study director · AbbVie

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion